問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Radiation Therapy

Division of Hematology & Oncology

Division of Thoracic Medicine

E-DA Hospital (在職)

Division of Hematology & Oncology

E-DA Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

更新時間:2023-09-19

饒坤銘
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

95Cases

2025-03-31 - 2028-01-31

Phase I

Active
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)
  • Condition/Disease

    Metastatic Solid Tumor、 Advanced Solid Tumor

  • Test Drug

    Intravenous drip injection

Participate Sites
10Sites

Recruiting10Sites

2025-11-01 - 2027-08-22

Phase II

Not yet recruiting
A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
  • Condition/Disease

    Nausea 、Vomiting 、Drug-Related Side Effects and Adverse Reactions 、Neoplasms

  • Test Drug

    subcutaneous injection

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2028-12-31

Phase I/II

Not yet recruiting
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)
  • Condition/Disease

    Colorectal Cancer (Diagnosis) 、Colorectal Cancer Metastatic、 Colorectal Cancer (CRC)、 Immunotherapy

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
7Sites

Recruiting7Sites

2025-11-07 - 2029-09-25

Phase III

Not yet recruiting
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)
  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Injectables

Participate Sites
8Sites

Recruiting8Sites

2012-11-30 - 2017-06-30

Phase IV

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2009-10-15 - 2011-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2019-11-01 - 2024-05-13

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2024-04-01 - 2028-01-31

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2020-12-15 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-08-31 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites